PTEN and prostate cancer: EGCG has revealed capacity to increase the expression of tumor suppressor gene p53 [82,83] and Phosphatase and tensin homolog (PTEN) [84] and cyclin-dependent kinase inhibitors p21 and p27 [83,85] in different cancer cell lines, including breast, pancreas and prostate cancer.